Advertisement

Die Behandlung des metastasierten Mammacarcinoms

  • Christoph Wiltschke
  • Christoph Zielinski
Chapter
  • 15 Downloads
Part of the Onkologie heute book series (ONKOLOGIE)

Zusammenfassung

Das metastasierte Mammacarcinom ist ein signifikantes und zunehmendes Problem in der westlichen Welt. Trotz zunehmender Verbesserungen durch Screeningmethoden werden noch immer viele Frauen mit Mammacarcinom erst im metastasierten Stadium diagnostiziert, entweder aufgrund von mangelnder Vorsorgeuntersuchungen oder aufgrund eines biologisch besonders aggressiven Tumors. Derzeit kann man davon ausgehen, daß etwa 5–7% der neu diagnostizierten Mammacarcinome metastasiert sind. Weiters steht fest, daß trotz deutlicher Verbesserungen in der adjuvanten Therapie des Mammacarcinoms ein Teil der Patientinnen ein Rezidiv erleiden und/oder konsekutiv metastasieren wird. Epidemiologisch können wir davon ausgehen, daß 24–30% der Lymphknoten-negativen und 50–60% der Lymphknoten-positiven Patientinnen zum Teil trotz adjuvanter Therapie rezidivieren werden. Es stellt somit die Behandlung des metastasierten Mammacarcinoms ein signifikantes Problem in der Onkologie dar, insbesonders als man zugeben muß, daß sich die Mortalität des Mammacarcinoms seit 1930 nicht wesentlich geändert hat, also sich die Behandlung des fortgeschrittenen Mammacarcinoms nicht eindeutig gebessert hat.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Beatson GT (1896) On the treatment of inoperable cases of carcinogen of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet 2: 104–107, 162–167.CrossRefGoogle Scholar
  2. [2]
    Bezwoda WR, Seymour L, Dansey RD (1995) High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial [see comments]. J Clin Oncol 13(10): 2483–2489.PubMedGoogle Scholar
  3. [3]
    Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up [see comments]. N Engl J Med 332(14): 901–906.PubMedCrossRefGoogle Scholar
  4. [4]
    Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D, Giovanelli E (1983) Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study. Cancer 51(4): 581–588.PubMedCrossRefGoogle Scholar
  5. [5]
    Eddy DM (1992) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer [published erratum appears in J Clin Oncol 10(10): 1655–1658] [see comments]. J Clin Oncol 10(4): 657–670.PubMedGoogle Scholar
  6. [6]
    Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E (1997) A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 13(6): 319–326.PubMedCrossRefGoogle Scholar
  7. [7]
    Flamm Honig S (1996) Treatment of metastatic disease. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds.) Diseases of the Breast. Lippincott-Raven, Philadelphia, S. 669–734.Google Scholar
  8. [8]
    Frassineti GL, Zoli W, Silvestro L, Serra P, Milandri C, Tienghi A, Gianni L, Gentile A, Salzano E, Amadori D (1997) Paclitaxel plus doxorubicin in breast cancer: An Italian experience. Semin Oncol 24(Suppl 17): S17–19–S17–25.PubMedGoogle Scholar
  9. [9]
    Goldhirsch A, Gelber RD, Price KN, Castiglione M, Coates AS, Rudenstam CM, Collins J, Lindtner J, Hacking A, Marini G (1994) Effect of systemic adjuvant treatment on first sites of breast cancer relapse [see comments]. Lancet 343(8894): 377–381.PubMedCrossRefGoogle Scholar
  10. [10]
    Henderson IC (1983) Chemotherapy of breast cancer. A general overview. Cancer 51(Suppl 12): 2553–2559.PubMedCrossRefGoogle Scholar
  11. [11]
    Hortobagyi GN, Holmes FA (1996) Single-agent paclitaxel for the treatment of breast cancer: An overview. Semin Oncol 23(Suppl 1): 4–9.PubMedGoogle Scholar
  12. [12]
    Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD (1998) Long-term prevention of skeletal complications of metastatic breast cancer with Pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16(6): 2038–2044.PubMedGoogle Scholar
  13. [13]
    Hug V, Hortobagyi GN, Drewinko B, Finders M (1985) Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro. J Clin Oncol 3(12): 1672–1677.PubMedGoogle Scholar
  14. [14]
    Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, Kilany S (1996) Efficacy of Pamidronate in breast cancer with bone metastases: A randomized double-blind placebo controlled multicenter study. Acta Oncol 35(Suppl 5): 73–74.PubMedCrossRefGoogle Scholar
  15. [15]
    Jain S, Fisher C, Smith P, Millis RR, Rubens RD (1993) Patterns of metastatic breast cancer in relation to histological type. Eur J Cancer 15: 2155–2157.CrossRefGoogle Scholar
  16. [16]
    Osborne CK, Yochmowitz MG, Knight WA, McGuire WL (1980) The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer 46: 2884–2888.PubMedCrossRefGoogle Scholar
  17. [17]
    Perez Carrion R, Alberala Candel V, Calabresi F, Michel RT, Santos R, Delozier T, Goss P, Mauriac L, Feuilhade F, Freue M (1994) Comparison of the selective aroma-tase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer. Ann Oncol 5(Suppl 7): S19–S24.Google Scholar
  18. [18]
    Peters WP (1995) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes. Important Adv Oncol: 215–230.Google Scholar
  19. [19]
    Piccart MJ, Di Leo A (1997) Future perspectives of docetaxel (Taxotere) in front-line therapy. Semin Oncol 24(Suppl 10): S10–27–S10–33.Google Scholar
  20. [20]
    Sherry MM, Greco FA, Johnson DH, Hainsworth JD (1986) Breast cancer with skeletal metastases at initial diagnosis. Distinctive clinical characteristics and favorable prognosis. Cancer 58(1): 178–182.PubMedCrossRefGoogle Scholar
  21. [21]
    Valagussa P, Bonadonna G, Veronesi U (1978) Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 41(3): 1170–1178.PubMedCrossRefGoogle Scholar
  22. [22]
    Van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, Hermans J, van Emmerik B, van Dam FS, van den Bos B, Bijvoet OL, Cleton FJ (1991) The effect of supportive Pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. Eur J Cancer 27(5): 544–549.PubMedCrossRefGoogle Scholar
  23. [23]
    Walter P, Green S, Greene G, Krust A, Bornert J-M, Jeltsch J-M, Staub A, Jensen E, Scrace G, Waterfield M (1985) Cloning of the human estrogen receptor cDNA. Proc Natl Acad Sci USA 82: 7889–7893.PubMedCrossRefGoogle Scholar
  24. [24]
    Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, Takue Y, Narabayashi M, Adachi I, Takashima S (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer [In Process Citation]. J Clin Oncol 16(7): 2401–2408.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 1999

Authors and Affiliations

  • Christoph Wiltschke
    • 1
  • Christoph Zielinski
    • 2
  1. 1.Univ.-Klinik für Innere Medizin IÖsterreich
  2. 2.Extraordinariat für internistisch-experimentelle OnkologieKlinik für innere Medizin I und Ludwig-Boltzmann-Institut für klinisch-experimentelle Onkologie WienÖsterreich

Personalised recommendations